Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | July 2010 |
| End Date: | January 2011 |
A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects
on fasting plasma glucose (FPG).
on fasting plasma glucose (FPG).
Inclusion Criteria:
- Type 2 diabetes mellitus
- Drug naive or on stable metformin therapy
- HbA1c 7-10%
- FPG ≤ 240mg/dL
Exclusion Criteria:
- History of myocardial infarction, coronary angioplasty or bypass grafts, valvular
disease or repair, unstable angina pectoris, transient ischemic attack, or
cerebrovascular accidents within six months prior to entry into the study
- Congestive heart failure
- Active liver disease
- Impaired renal function
- Hepatitis C, B and HIV
This list is not inclusive; additional information is provided in the protocol
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials